Hi GMFJ,
I appreciate your comments & the POV shift. A useful tool. Your hypothetical about Pfizer, Merck & Novartis is thought-provoking.
It may appear a distraction, but I’d like to pose another question in order to add a little extra substance to the thought-experiment i.e. why & how exactly is it that in 2022 not one of Pfizer, Merck & Novartis yet have the benefit of an ODAC 9-1 vote endorsing the effectiveness of an allogeneic somatic HCT/P therapy product?
I’d submit this question is important because, as you note, MSB does. As I see it, this leg of the thought-experiment might logically have to be answered first, before we’d have enough information to address properly your v. good question.
Thoughts?
Cell Therapy News/Articles, page-14423
-
- There are more pages in this discussion • 3,587 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |